The last patient has been enrolled in Allegro Ophthalmics’ phase 2b trial of Luminate for patients with diabetic macular edema, according to a company press release.Luminate (ALG-1001) will be studied in 120 patients in the double masked, placebo-controlled, 6-month DEL MAR trial.
Zika: Could virus spread via contact with sweat, tears?
Doctors discuss a rare case of a patient who died from Zika virus and the possibility of transmission to a second patient via contact with sweat and tears.
Speaker makes a case for not using latest generation fluoroquinolones
At the Hawaiian Eye meeting, Ayman Naseri, MD, gives five reasons why he does not prefer to use the latest generation topical fluoroquinolones as his approach to prophylaxis in cataract surgery.
Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate® for Non-Proliferative Diabetic Retinopathy
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–Allegro Ophthalmics completed enrollment in its PACIFIC Phase 2b clinical trial evaluating the safety and efficacy of Luminate® in inducing PVD in patients with non-proliferative diabetic retinopathy.
Mati Therapeutics Selected to Present at Ocular Innovation Summit
AUSTIN, Texas–(BUSINESS WIRE)–Mati Therapeutics Inc. announced that it has been selected to present at the annual Ocular Innovation Summit on October 13, 2016 in Chicago.
Ocular Hypertension Therapeutics Market H2 2016: Pipeline Review of 23 Companies & 39 Drug Profiles – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Ocular Hypertension – Pipeline Review, H2 2016” report to their offering. Ocular Hypertension Ocular hypertension occurs when the pressure in the eye (known as intraocular…